The current use of botulinum toxin

Journal of Clinical Neuroscience

Volumn 7, Issue 5, 2000, Pages 389-394

  Mahant, N ^a   Clouston, P D ^a   Lorentz, I T ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Botulinum toxins; Dystonia; Immunoresistance; Spasticity

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A;

ACETYLCHOLINE RELEASE; CLOSTRIDIUM BOTULINUM; DENERVATION; DRUG EFFICACY; DRUG USE; DYSTONIA; HEMIFACIAL SPASM; HYPERHIDROSIS; IMMUNITY; NERVE ENDING; PRIORITY JOURNAL; REVIEW; SEROTYPING; SPASTICITY; SYNAPSE VESICLE;

EID: 0033812358     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1054/jocn.2000.0684     Document Type: Review

References (122)

1. Historical perspective
2. Botulinum toxin: Historical perspective and potential new indications
3. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin
4. Crystal structure of botulinum neurotoxin type A and implications for toxicity
5. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology
6. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site
7. Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle
8. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals
9. Dose standardization of botulinum toxin
10. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia
11. DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - Assuming a ratio of 4:1
12. Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm
13. Gallbladder dysfunction induced by botulinum A toxin
14. Pain and remote weakness in limbs injected with botulinum toxin A for writer's cramp
15. Brachial plexopathy after botulinum toxin administration for cervical dystonia
16. Brachial plexopathy after botulinum toxin injections
17. Myasthenic crisis after botulinum toxin
18. Necrotising fasciitis as a complication of botulinum toxin injection
19. Response and immunoresistance to botulinum toxin injections
20. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections
21. The EBD test - A clinical test for the detection of antibodies to botulinum toxin type A
22. Consensus statement for the management of focal dystonias
23. Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications
24. Treatment of hemifacial spasm with botulinum toxin
25. Hemifacial spasm treated with botulinum A toxin injection
26. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: A report of 175 cases
27. Hemifacial spasm: Clinical findings and treatment
28. Treatment of hemifacial spasm with botulinum toxin
29. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm
30. Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm
31. Botulinum toxin therapy in hemifaciai spasm: Clinical and electrophysiologic studies
32. Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations
33. Concept and classification of dystonia
34. The pathophysiology of primary dystonia
35. Dystonia: Recent advances
36. Botulinum toxin injection for spasmodic torticollis: Increased magnitude of benefit with electromyographic assistance
37. Pretarsal application of botulinum toxin for treatment of blepharospasm
38. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy; report of two cases
39. Motor persistence of orbicularis oculi muscle in eyelid-opening disorders
40. Frontalis suspension in the treatment of essential blepharospasm unresponsive to botulinum-toxin therapy: Long-term results
41. Tongue protrusion dystonia: Treatment with botulinum toxin
42. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin
43. Treatment of oromandibular dystonia with botulinum toxin
44. Botulinum toxin injection for the treatment of oromandibular dystonia
45. Botulinum A toxin for cranial-cervical dystonia: A double-blind, placebo-controlled study
46. Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial
47. Double-blind study of botulinum toxin in spasmodic torticollis
48. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: A double-blind study on twenty-three patients
49. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group
50. Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin
51. Treatment of idiopathic spasmodic torticollis with botulinum-A toxin: A pilot study of 19 patients
52. Local treatment of spasmodic torticollis with botulinum toxin
53. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: A review of 22 studies
54. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia
55. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia
56. Laryngeal dystonia (spasmodic dysphonia): Observations of 901 patients and treatment with botulinum toxin
57. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia
58. Botulinum toxin in writer's cramp: Objective response evaluation in 31 patients
59. Botulinum toxin in the treatment of writer's cramp
60. Treatment of non-occupational limb and trunk dystonia with botulinum toxin
61. Writer's cramp: Treatment with botulinum toxin injections
62. Double-blind trial of botulinum toxin for treatment of focal hand dystonia
63. Writer's cramp: The experience with botulinum toxin injections in 25 patients
64. Treatment of upper limb dystonia with botulinum toxin
65. Symposium synopsis
66. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion
67. A clinical overview of txeatment decisions in the management of spasticity
68. Traditional pharmacological treatments for spasticity. Part I: Local treatments
69. Traditional pharmacological txeatments for spasticity. Part II: General and regional treatments
70. Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity
71. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group
72. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: A randomized, double-blind trial
73. Comparison of two injection techniques using botulinum toxin in spastic hemiplegia
74. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: A randomised prospective trial
75. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients
76. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure
77. One hundred cases of anal fissure treated with botulin toxin: Early and long-term results
78. Repeat botulin toxin injections in anal fissure: In patients with relapse and after insufficient effect of first treatment
79. Therapeutic effects of different doses of botulinum toxin in chronic anal fissure
80. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure
81. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms
82. Botulinum A neurotoxin for axillary hyperhidrosis. No sweat Botox
83. Focal hyperhidrosis: Effective treatment with intracutaneous botulinum toxin
84. Botulinum toxin therapy for palmar hyperhidrosis
85. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin
86. Understanding botulinum toxin. Surgical anatomy of the frown, forehead, and periocular region
87. Cosmetic indications for botulinum A toxin
88. Sleep bruxism
89. Bruxism after brain injury: Successful treatment with botulinum toxin-A
90. Botulinum toxin injections for voiding dysfunction following SCI
91. Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin
92. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease
93. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: A prospective study in 24 spinal cord injury patients
94. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study
95. Botulinum toxin type B: An open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients
96. Botulinum toxin type B in the treatment of cervical dystonia: A pilot study
97. Human response to botulinum toxin injection: Type B compared with type A
98. Botulinum neurotoxin serotype C: A novel effective botulinum toxin therapy in human
99. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans
100. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A
101. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A
102. Botulinum toxin type F for treatment of dystonia: Long-term experience
103. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension
104. Treating achalasia: From whalebone to laparoscope
105. Laparoscopic Heller's myotomy or botulinum toxin injection for management of esophageal achalasia. Patient choice and treatment outcomes
106. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: A randomised trial
107. Botulinum toxin A improves muscle spasms and rigidity in stiff-person syndrome
108. Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A
109. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor
110. Botulinum toxin treatment of essential head tremor
111. Botulinum toxin in the treatment of dystonic tics
112. Clinical and physiologic implications of thalamic surgery for disorders of sensory communication. 2. Intention tremor, dystonia, Wilson's disease and torticollis
113. Sensory feedback therapy of spasmodic torticollis and dystonia: Results in treatment of 55 patients
114. A primate genesis model of focal dystonia and repetitive strain injury: I. Learning-induced dedifferentiation of the representation of the hand in the primary somatosensory cortex in adult monkeys
115. Constraint-induced movement therapy for focal hand dystonia in musicians